

Sunday, August 14, 2011

14:00 - Check-in at housing facility

14:30 – 16:00 Welcome Refreshments

17:30 – 19:00 Dinner (Café Ventana)

19:00 – 19:05 Welcome Remarks: Dong-Er Zhang

19:05 – 21:15 Session I: Normal and cancer stem cell survival and expansion

Chairs: Stephen Nimer & Ewan Cameron

19:05- 19:25 I-1 **Daniel Tenen** (Cancer Science Institute, NUS & Harvard Medical School)
Runx regulation of long noncoding and extracoding RNAs in hematopoiesis

19:25 – 19:40 I-2 **Joanna Tober** (Nancy A. Speck) (University of Pennsylvania)
Defining the transition from Runx1 dependence to independence during hematopoietic cell formation.

19:40 – 19:55 I-3 **Gareth Brady** (Paul Farrell) (Imperial College, UK)
Differential effects of RUNX1 splice variants on Lymphoblastoid cell line growth

19:55 – 20:05 I-4 **Yukiko Komeno** (Dong-Er Zhang) (Univ. of California San Diego, USA)
“Runx1-IRES-GFP knock-in” mice as a model of “Runx1a KO” mice: changes in hematopoietic stem cells in stable state and under stress

20:05 – 20:25 **Break**

Chairs: James Mulloy & Suk-Chul Bae

20:25 - 20:45 I-5 **Stefano Stifani** (McGill University, Canada)
Involvement of Runx1 in the development of motor neurons

20:45 – 21:00 I-6 **Cornelia Scheitz** (Tudorita Tumber) (Cornell University, USA)
The skin stem cell regulator Runx1 is essential for initiation and maintenance of skin squamous cell carcinoma

21:00 – 21:20 I-7 **Ya Huei Kuo** (City of Hope Beckman Research Institute, USA)
Alcam mediated interaction regulates self-renewal of hematopoietic stem cells and Cbf β -SMMHC induced leukemogenesis.

21:20 **Adjourn**

Monday, August 15, 2011

7:00 – 9:00 **Breakfast** **(Café Ventana)**

Session II: **Mechanisms of cell-fate specification in development and hematopoiesis**

9:00 – 11:40

Chairs: Jennifer Westendorf & Yoram Groner

9:00 – 9:20 II-1 **Karen Blyth** (Beatson Institute for Cancer Research, UK)
Dissecting the role of Runx2 in mammary development and breast cancer

9:20 – 9:40 II-2 **Peter Gergen** (Stony Brook University, USA)
Overlapping but distinct roles of Odd-paired and the J AK/Stat pathway in activating the Runt target sloppy-paired-1 during Drosophila segmentation.

9:40 – 10:00 II-3 **Marella de Bruijn** (University of Oxford, UK)
Commitment of endothelial cells to a hematopoietic fate in the AGM occurs before E10.5

10:00 – 10:20 II-4 **Motomi Osato** (National University of Singapore)
Disruption of Runx family genes leads to bone marrow failure and myeloproliferative disorder due to a defective Fanconi anemia-related DNA damage repair pathway

10:20 – 10:40 **Break**

Chairs: Ditsa Levanon & Paul Liu

10:40 – 11:00 II-5 **Alan D. Friedman** (Johns Hopkins University, USA)
Runx1 absence or dominant inhibition reduces Cebpa transcription to favor monopoiesis over granulopoiesis

11:00 – 11:20 II-6 **Alan B. Cantor** (Children's Hospital, Boston, USA)
Tyrosine phosphorylation of Runx1 by src family kinases.

11:20 – 11:40 II-7 **Issay Kitabayashi** (National Cancer Center Research Inst., Japan)
Specification of cell fates by RUNX-interacting histone acetyltransferase MOZ

11:40 – 13:00 **Lunch** **(Café Ventana)**

13:00 – 15:00 **Poster Session**

15:00 – 18:00 **Afternoon Networking (Outing: Torrey Pines State Reserve)**

17:30 – 19:00 **Dinner** **(Café Ventana)**

**Session III:
19:00 – 21:40**

Leukemia & Lymphoma, Bone Biology (A)

Chairs: Carol Stocking & Lucio Castilla

- 19:00 – 19:20 III-1 **Ichiro Taniuchi** (RIKEN, RCAI, Kanagawa, Japan)
Genetic and molecular analyses of Runx-dependent transcriptional silencers during thymocytes development.
- 19:20 – 19:40 III-2 **Alex Tonks** (Cardiff University, UK)
The RUNX1-ETO target gene, CD200 inhibits memory Th1 cell function and is associated with increased frequencies of regulatory T-cells in acute myeloid leukemia.
- 19:40 – 20:00 III-3 **Hironori Harada** (Hiroshima University, Japan)
Molecular mechanisms to produce myeloid neoplasms by RUNX1 or MLL chimeras in human CD34⁺ cells
- 20:00 – 20:20 III-4 **Jianjun Chen** (University of Chicago, USA)
The role of miR-126 in acute myeloid leukemia
- 20:20 – 20:40 **Break**
- 20:40 – 21:00 III-5 **Chairs: Hyun Ryoo & Jane Lian**
Takashi Yamashiro (Okayama University, Japan)
Core binding factor beta (Cbf β) functions in the maintenance of stem cells and orchestrates continuous proliferation and differentiation in mouse incisors
- 21:00 – 21:20 III-6 **Je-Yong Choi** (Kyungpook National University, Korea)
Essential role of Core binding factor- β in cortical bone mass by regulating Runx2 stability
- 21:20 – 21:40 III-7 **Jennifer J. Westendorf** (Mayo Clinic, USA)
Runx2 regulates Axin2 modulation of mesenchymal cell fate in cranial sutures
- 21:40 **Adjourn**

Tuesday, August 16, 2011

7:00 – 9:00 Breakfast (Café Ventana)

**Session IV:
9:00 – 11:50 Leukemia & Lymphoma, Bone Biology (B)**

Chairs: Marella de Bruijn & Yoshi Ito

9:00 – 9:20 IV-1 **Carol Stocking** (Heinrich-Pette-Institute, Germany)
RUNX1 in-B-cell development and leukemia.

9:20 – 9:4 IV-2 **Gang Huang** (Cincinnati Children's Hospital, USA)
MLL-PTD causes hypomorph condition of CBF complex
(RUNX1/CBF β) and predisposes the abnormal HSPCs to clonal
expansion

9:40 – 10:00 IV-3 **James C. Mulloy** (Cincinnati Children's Hospital, USA)
Dual role of RUNX1 in human myeloid neoplasms

10:00 – 10:20 IV-4 **Gillian Borland** (Ewan Cameron) (University of Glasgow, UK)
A role for endogenous Runx1 in lymphoma maintenance?

10:20 – 10:50 **Break**

Chairs: Je-Yong Choi & Gary Stein

10:50 – 11:10 IV-5 **Jane Lian** (Univ. of Massachusetts Medical School, USA)
Runx2 Controls the Skeletal Landscape

11:10 – 11:30 IV-6 **Hyun-Mo Ryoo** (Seoul National University, Korea)
Loss-of-Pin1 impairs osteoblastogenesis by reducing Runx2
protein stability

11:30 – 11:50 IV-7 **Andre van Wijnen** (Univ. of Massachusetts Medical School, USA)
A Program of MicroRNAs Controls Osteogenic Lineage
Progression by Targeting Transcription Factor RUNX2

11:50 – 13:30 **Lunch (Café Ventana)**

**Session V:
14:00 – 17:20**

Development and Cancer

Chairs: Jim Neil & Peter Gergen

- 14:00 – 14:20 V-1 **Yoram Groner** (The Weizmann Institute of Science, Israel)
The Role of Alternative Promoter Usage in Runx3 Biology
- 14:20 – 14:40 V-2 **Ditsa Levanon** (Weizmann Institute of Science, Israel)
Transcription Regulation of Cytolytic Effector Cells by Runx3
- 14:40 – 15:00 V-3 **You-Mie Lee** (Kyungpook National University, Korea)
Methylation by G9a HMT impairs the function and subcellular localization of RUNX3
- 15:20 – 15:40 V-4 **Han-Sung Jung** (Yonsei University, Korea)
Abnormal liver differentiation and impaired angiogenesis in mice lacking Runx3
- 15:40 – 16:00 V-5 **Lin-Feng Chen** (University of Illinois at Urbana-Champaign, USA)
RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α

16:00 – 16:20 **Break**

Chairs: Stefano Stefani & Nancy Speck

- 16:20 – 16:40 V-6 **Yoshiaki Ito** (Cancer Science Institute of Singapore, Singapore)
Runx3 protects gastric epithelial cells against EMT-induced plasticity and Lgr5-expressing tumorigenic subpopulation
- 16:40 – 17:00 V-7 **Suk-Chul Bae** (Chungbuk National Univ. Korea)
Identification of a mechanism of feedback regulation critical for the R-point decision.
- 17:00 – 17:20 V-8 **Stephen D. Nimer** (Memorial-Sloan Kettering Cancer Center, USA)
Effects of “histone modifying enzymes” on the function of AML1 and AML1-ETO

17:20 Adjorn

17:30 – 20:30 **Cocktail at the Bistro Patio**

19:00 – 22:00 **Reception Dinner at the Bistro**

Wednesday, August 17, 2011

7:00 – 9:00 **Breakfast** **(Café Ventana)**

Session VI: **Therapeutic targets and drug discovery**
8:40 – 11:30

Chairs: Ichiro Taniuchi & Motomi Osato

- 8:40 – 9:00 VI-1 **Paul Liu** (NHGRI, NIH, USA)
Development of novel targeted treatment for Core Binding Factor (CBF) leukemias
- 9:00 – 9:20 VI-2 **Lucio Castilla** (University of Massachusetts, USA)
Oncogenic THPO/MPL signaling in acute myeloid leukemia with RUNX1-ETO
- 9:20 – 9:40 VI-3 **J.-R. Joanna Yeh** (Massachusetts General Hospital, USA)
Discovering chemical suppressors of AML1-ETO in zebrafish
- 9:40 – 10:00 **Break**

Chairs: Issay Kitabayashi & Andre van Wijnen

- 10:00 – 10:20 VI-4 **Jörn Lausen** (Georg-Speyer Haus Institute for Biomedical Research, Germany)
The histone arginine methyl-transferase PRMT6 is a RUNX1 associated corepressor
- 10:20 – 10:40 VI-5 **Yogen Sauntharajah** (Cleveland Clinic, USA)
Runx1 regulation of corepressor/coactivator exchange by lineage-specifying transcription factors enables selective, p53-independent anti-leukemia therapy
- 10:40 – 10:55 VI-6 **Miao-Chia Lo** (Dong-Er Zhang) (Univ. of California San Diego, USA)
Combined gene expression and DNA occupancy profiling identifies JAK/STAT signaling as a valid therapeutic target of t(8;21) acute myeloid leukemia

10:55 – 11:25 **2012 Organizers/Round Table**

11:25 **Adjourn**

11:30 – 1:00 **Lunch** **(Café Ventana)**

POSTER PRESENTATIONS:

- P-1 Nras oncogenic mutation provides survival advantage to preleukemic progenitors and synergizes with CBF β -SMMHC in leukemia development**
Litng Xue (Lucio Castilla) (University of Massachusetts Medical School)
- P-2 Cis-regulatory contributions to the regulation of sloppy-paired-1 transcription initiation and elongation**
Saiyu Hang (Peter Gergen) (Stony Brook University, New York)
- P-3 CBF β is required in Ly6a-expressing cells for hematopoietic stem cell formation**
Yan Li (Nancy Speck) (University of Pennsylvania)
- P-4 Runx1 is required for Cbfb-MYH11 activity during primitive hematopoiesis**
Paul Liu (NHGRI, NIH, Bethesda Maryland)
- P-5 Negative Effects of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling in a Murine Model of t(8;21)-Induced Leukemia**
Ming Yan (Dong-Er Zhang) (University of California, San Diego)
- P-6 PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential**
Wei-Jong Shia (Dong-Er Zhang) (University of California, San Diego)
- P-7 COX/b-catenin signaling pathway mediates AML1-ETO function in leukemogenesis**
Yiyun Zhang (J.-R. Joanna Yeh) (Massachusetts General Hospital)
- P-8 S100A2, a target gene of RUNX3 and p53 in gastrointestinal cells**
Jason Koo (Yoshiaki Ito) (Cancer Science Institute of Singapore)
- P-9 Histone acetyltransferase MOZ and MORF are essential for hematopoiesis and self renewal of hematopoietic stem cells.**
Issay Kitabayashi (National Cancer Center Research Institute, Tokyo)

- P-10 The SALL4/Runx1 pathway in normal hematopoiesis**
Chong Gao (Li Chai) (Brigham and Women's Hospital, Boston, MA)
- P-11 Identification of RUNX as centrosome-associated proteins.**
Soak Kuan Lai (Yoshiaki Ito) (Cancer Science Institute of Singapore, NUS)
- P-12 Identification of a mechanism of feedback regulation critical for the R-point decision.**
Xin-Zi Chi (Suk-Chul Bae) (Chungbuk National University Korea)
- P-13 Epigenetic repression of the AML1/ETO target gene LAT2 and its effects upon myeloid differentiation**
Jesus Duque-Afonso (Michael Lubbert) (University of Freiburg)
- P-14 Development and Characterization specific, small-molecule inhibitors of CBF β -SMMHC**
Paul Bradley (Lucio Castilla) (University of Massachusetts Medical School)
- P-15 Alcam mediated interaction regulates self-renewal of hematopoietic stem cells and Cbf β -SMMHC induced leukemogenesis.**
Robin Jeannet (Ya Huei Kuo) (City of Hope)
- P-16 Notch regulation of runx1 expression in zebrafish endothelial cells.**
Emerald Butko (David Traver) (University of California San Diego)
- P-17 Abnormal liver differentiation and impaired angiogenesis in mice lacking Runx3**
Jong-Min Lee (Han-Sung Jung) (Yonsei University)
- P-18 Modeling *RUNX1* biallelic mutations associated with AML-M0 and AML-FPD in mice reveals importance of residual Runx1 function**
Kira Behrens (Carol Stockling) (Heinrich-Pette-Institute)